Anthem Biosciences IPO GMP has reached 17 percent ahead of the issue’s opening for public subscription on July 14.
The company has fixed a price band of Rs 540-570 per share for its Rs 3,395-crore IPO. At the upper end of the band, the company’s valuation stands at over Rs 31,800 crore. The issue will remain open from July 14 to July 16.
According to websites tracking grey market activity, the GMP for the IPO is around Rs 97 per share, suggesting an expected listing gain of nearly 17 percent. The premium reflects strong investor interest ahead of the launch.
The IPO is entirely an offer-for-sale (OFS) by the company’s promoters and existing shareholders. As a result, the company will not receive any proceeds from the issue.
Anthem Biosciences IPO: Should you subscribe?
Harshal Dasani, Business Head, INVasset PMS, said the IPO gives investors exposure to India’s rising role as a global CRDMO (Contract Research, Development and Manufacturing Organisation) player. Dasani noted that the company is targeting over 30 percent revenue growth in FY25 with EBITDA margins close to 37 percent.
He highlighted Anthem’s expansion plans, including a 50 percent increase in fermentation and synthesis capacity over the next 12–18 months, and said the company is well-placed to benefit from the global shift away from Chinese suppliers.
India’s CRDMO industry, currently valued at around $7.3 billion, is expected to double by 2028. Anthem’s peers include Divi’s Laboratories, Syngene International, Suven Life Sciences, and Sai Life Sciences.
However, Dasani cautioned that nearly 70 percent of Anthem’s revenue comes from its top five clients, indicating a concentration risk. He said post-IPO performance will depend on execution, diversification, and maintaining margins.
Shares of Anthem Biosciences will be listed on BSE and NSE on July 21. Allotment is likely to take place on July 17.
Anthem Biosciences operates as an innovation-led, technology-driven CRDMO, with integrated operations across drug discovery, development, and manufacturing. It also produces complex fermentation-based active pharmaceutical ingredients, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
